EE369 COST-EFFECTIVENESS ANALYSIS OF BIREOCICLIB VERSUS ABEMACICLIB IN HR+/HER2- ADVANCED OR METASTATIC BREAST CANCER: COMPARING MATCHING-ADJUSTED INDIRECT COMPARISON AND SIMULATED TREATMENT COMPARISON APPROACHES
Value in Health · 2026-06 · 29 (6) · S133
DOI: 10.1016/j.jval.2026.03.663 ↗Kurz gefasst
Fachartikel in der Zeitschrift Value in Health, 2026-06. Verfasst von Yu Chen und 6 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Chen, Y., Xie, Y., Yuan, X., Wu, J., Liu, F., Duan, X., & HU, M. (2026). EE369 COST-EFFECTIVENESS ANALYSIS OF BIREOCICLIB VERSUS ABEMACICLIB IN HR+/HER2- ADVANCED OR METASTATIC BREAST CANCER: COMPARING MATCHING-ADJUSTED INDIRECT COMPARISON AND SIMULATED TREATMENT COMPARISON APPROACHES. Value in Health, 29(6), S133. https://doi.org/10.1016/j.jval.2026.03.663
Vancouver
Chen Y, Xie Y, Yuan X, Wu J, Liu F, Duan X, et al. EE369 COST-EFFECTIVENESS ANALYSIS OF BIREOCICLIB VERSUS ABEMACICLIB IN HR+/HER2- ADVANCED OR METASTATIC BREAST CANCER: COMPARING MATCHING-ADJUSTED INDIRECT COMPARISON AND SIMULATED TREATMENT COMPARISON APPROACHES. Value in Health. 2026;29(6):S133. doi:10.1016/j.jval.2026.03.663
BibTeX
@article{Chen2026,
author = {Chen, Yu and Xie, Yuanbao and Yuan, Xinyue and Wu, Jingjing and Liu, Fei and Duan, xianghui and HU, MING},
title = {EE369 COST-EFFECTIVENESS ANALYSIS OF BIREOCICLIB VERSUS ABEMACICLIB IN HR+/HER2- ADVANCED OR METASTATIC BREAST CANCER: COMPARING MATCHING-ADJUSTED INDIRECT COMPARISON AND SIMULATED TREATMENT COMPARISON APPROACHES},
journal = {Value in Health},
year = {2026},
volume = {29},
number = {6},
pages = {S133},
doi = {10.1016/j.jval.2026.03.663}
}
EUVIMED